Induction by antipsychotics of "win-shift" in the drug discrimination paradigm

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 1, 2007, Pages 288-298

  Colpaert, Francis ^a   Koek, Wouter ^b   Kleven, Mark ^c   Besnard, Joel ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c Yaupon Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CYCLOPENT 1 ENYL BENZYL) [2 (2,2 DIMETHYL 2,3 DIHYDRO BENZOFURAN 7 YLOXY)ETHYL]AMINE FUMARATE; (3 EXO) 8 BENZOYL N [[7 CHLORO 2,3 DIHYDRO 1,4 BENZODIOXIN 1 YL]METHYL] 8 AZABICYCLO[3,2,1]OCTANE 3 METHANAMINE; 1 (2,3 DIHYDRO BENZO[1,4]DIOXIN 5 YL) 4 [5 (4FLUOROPHENYL) PYRIDIN 3 YLMETHYL] PIPERAZINE; 5 [4 [5 (4 FLUOROPHENYL) 3 PYRIDINYLMETHYL] 1 PIPERAZINYL] 1,4 BENZODIOXAN; ALIPHATIC AMINE; ARIPIPRAZOLE; BIFEPRUNOX; CHLORPHENIRAMINE; CHLORPROMAZINE; CLOZAPINE; COCAINE; DIAZEPAM; DIZOCILPINE; EMONAPRIDE; F 15063; FENTANYL; FUMARIC ACID DERIVATIVE; HALOPERIDOL; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; PHENTOLAMINE; PIPERAZINE DERIVATIVE; PRAZOSIN; PROPRANOLOL DERIVATIVE; RACLOPRIDE; RISPERIDONE; RITANSERIN; SCOPOLAMINE; SODIUM CHLORIDE; SSR 181507; THIORIDAZINE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIORAL SCIENCE; CONTROLLED STUDY; DELIRIUM; DRUG DISCRIMINATION; DRUG EFFICACY; DRUG SELECTIVITY; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYSTEM; FOOD; HALLUCINATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REWARD;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZOFURANS; BENZYLAMINES; CHLORPROMAZINE; CONDITIONING, OPERANT; CYCLOPENTANES; DISCRIMINATION LEARNING; FENTANYL; HALOPERIDOL; MALE; RATS; RATS, SPRAGUE-DAWLEY; REWARD;

EID: 34250709020     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.119446     Document Type: Article

References (41)

1. Andrezina R, Josiassen, Marcus RN, Oren DA, Manos G, Stock E, and Carson WH, and Iwamoto T (2006) Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with haloperidol. Psychopharmacology 188:281-292.
2. Berridge KC (2007) The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 191:391-431.
3. Blin O (1999) A comparative review of new antipsychotics. Can J Psychiatry 44:235-244.
4. Bobon J, Pinchard A, Collard J, and Bobon PB (1972) Clinical classification of neuroleptics, with special reference to their antimanic, antiautistic, and ataraxic properties. Compr Psychiatry 13:123-131.
5. Broekkamp CLE, Oosterloo SK, Berendsen HHG, and van Delft AML (1988) Effect of metergoline, fenfluramine, and 8-OD-DPAT on catalepsy induced by haloperidol or morphine. Naunyn-Schmiedeberg's Arch Pharmacol 338:191-195.
6. Claustre Y, Peretti DD, Brun P, Gueudet C, Allouard N, Alonso R, Lourdelet J, Oblin A, Damoiseau G, Francon D, et al. (2003) SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile. Neuropsychopharmacology 28:2064-2076.
7. Colonna L, Petit M, and Lépine JP (1989) Dictionnaire des Neuroleptiques, JB Baillière, Paris, France.
8. Colpaert FC (1978) Some properties of drugs as physiological signals: the FR procedure and signal detection theory, in Stimulus Properties of Drugs: Ten Years of Progress (Colpaert FC and Rosecrans JA eds) pp 217-242, Elsevier, Amsterdam, The Netherlands.
9. Colpaert FC (1987) Drug discrimination: methods of manipulation, measurement and analysis, in Methods of Assessing the Reinforcing Properties of Abused Drugs (Bozarth MA ed) pp 341-372, Springer, New York.
10. Colpaert FC and Janssen PAJ (1984) Agonist and antagonist effects of prototype opiate drug in rats discriminating fentanyl from saline: characteristics of partial generalization. J Pharmacol Exp Ther 230:193-199.
11. Colpaert FC, Koek W, and Bruins Slot LA (2001) Evidence that mnesic states govern normal and disordered memory. Behav Pharmacol 12:575-589.
12. Colpaert FC, Niemegeers CJE, and Janssen PAJ (1977) Differential haloperidol effect on two indices of fentanyl-saline discrimination. Psychopharmacology 53:169-173.
13. Colpaert FC, Niemegeers CJE, and Janssen PAJ (1980a) Factors regulating drug cue sensitivity: limits of discriminability and the role of a progressively decreasing training dose in fentanyl-saline discrimination. J Pharmacol Exp Ther 212:474-480.
14. Colpaert FC, Niemegeers CJE, and Janssen PAJ (1980b) Factors regulating drug cue sensitivity: the effects of training dose in fentanyl-saline discrimination. Neuropharmacology 19:705-713.
15. 4 partial agonist properties: (II) Activity in models of positive symptoms of schizophrenia. Br J Pharmacol 151:253-265.
16. Dietrich A (2003) Functional neuroanatomy of altered states of consciousness: the transient hypofrontality hypothesis. Conscious Cogn 12:231-256.
17. Dietrich A, Taylor JT, and Passmore CE (2001) AVP(4-8) improves concept learning in PFC-damaged but not in hippocampal-damaged rats. Brain Res 919:41-47.
18. Ettenberg A and Camp HC (1986) Haloperidol induces a partial reinforcement extinction effect in rats: implications for a dopamine involvement in food reward. Pharmacol Biochem Behav 25:813-821.
19. Ferguson HJ, Cobey S, and Smith BH (2001) Sensitivity to a change in reward is heritable in the honeybee, Apis mellifera. Anim Behav 61:527-534.
20. Flach J (1975) Neuroleptiques: Vingt ans Après, p 277, Specia, Paris, France.
21. Gerard A, Loo H, Olie JP, and Zarifian E (1984) Séminaire de Psychiatrie Biologique, p 158, Fharmuka SF, Gennevilliers, France.
22. Goudie AJ, Atkinson J, and West CR (1986) Discriminative properties of the psychostimulant dl-cathinone in a two-lever operant task. Lack of evidence for dopaminergic mediation. Neuropharmacology 25:85-94.
23. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
24. Koek W, Kleven MS, and Colpaert FC (1995) Effects of the NMDA antagonist, dizocilpine, in various drug discriminations: characterization of intermediate levels of drug lever selection. Behav Pharmacol 6:590-600.
25. Hamann J, Ruppert A, Auby P, Pugner K, and Kissling W (2003) Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription base. Int Clin Psychopharmacol 18:237-242.
26. Harlow HF (1949) The formation of learning sets. Psychol Rev 56:51-65.
27. Kapur S, Mizrahi R, and Li M (2005) From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 79:59-68.
28. 2 receptors. Psychopharmacology 112:S40-S54.
29. Matsen FA and Nowak MA (2004) Win-stay, lose-shift in language learning from peers. Proc Natl Acad Sci U S A 101:18053-18057.
30. McCreary AC, Glennon JC, Ashby CR Jr., Meltzer HY, Li Z, Reinders JH, Hesselink MB, Long SK, Herremans AH, van Stuivenberg H, et al. (2007) SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-fluoro-phenyl) -pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug. Neuropsychopharmacology 32:78-94.
31. Newman-Tancredi A, Assié MB, Martel JC, Cosi C, Bruins Slot L, Palmier C, Rauly-Lestienne I, and Cussac D (2007) F 15063, a potential antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (I) in vitro receptor affinity profile. Br J Pharmacol 151:237-252.
32. Niemegeers CJ and Janssen PA (1979) A systematic study of the pharmacological activities of dopamine antagonists. Life Sci 24:2201-2216.
33. Restle F (1958) Toward a quantitative description of learning set data. Psychol Rev 65:77-91.
34. Salamone JD, Correa M, Minigote S, and Weber SM (2003) Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry and drug abuse. J Pharmacol Exp Ther 305:1-8.
35. Schmidt WJ and Beninger RJ (2006) Behavioural sensitization in addiction, schizophrenia, Parkinson's disease and dyskinesia. Neurotox Res 10:161-166.
36. Schmidt WJ, Tzschentke TM, and Kretschmer BD (1999) State-dependent blockade of haloperidol-induced sensitization of catalepsy by MK-801. Eur J Neurosci 11:3365-3368.
37. Simon P, Lecrubier Y, and Puech AJ (1984) Classification des neuroleptiques. Rev Prat 34:589-594.
38. Tremblay L, Hollerman JR, and Schultz W (1998) Modifications of reward expectation-related neuronal activity during learning in primate striatum. J Neurophysiol 80:964-977.
39. Wadenberg ML and Hicks PB (1999) The conditioned avoidance response test reevaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851-862.
40. Wise RA (2004) Dopamine, learning and motivation. Nat Rev Neurosci 5:483-494.
41. Wise RA, Spindler J, and Legault L (1978) Major attenuation of food reward with performance-sparing doses of pimozide in the rat. Can J Psychol 32:77-85.